Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697928 | 0.85 | ERN1 (0.45) | ERN1L3MBTL1METAP2ALOX15HTT | |
| SCHEMBL31325771 | 0.80 | L3MBTL1 (0.45) | L3MBTL1METAP2ALDH1A1ALOX15HTT | |
| SCHEMBL31325753 | 0.80 | L3MBTL1 (0.45) | L3MBTL1METAP2ALDH1A1HTTLMNA | |
| SCHEMBL4700610 | 0.79 | L3MBTL1 (0.49) | L3MBTL1METAP2ALDH1A1ALOX15HTT | |
| SCHEMBL31325694 | 0.77 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1HTTLMNA | |
| SCHEMBL9964039 | 0.76 | DYRK1A (0.53) | L3MBTL1ALDH1A1HTTLMNA | |
| SCHEMBL2561503 | 0.75 | L3MBTL1 (0.57) | ERN1L3MBTL1ALDH1A1ALOX15HTT | |
| SCHEMBL11617702 | 0.75 | KMT2A (0.48) | L3MBTL1ALDH1A1HTT | |
| SCHEMBL69177 | 0.75 | L3MBTL1 (0.64) | L3MBTL1ALDH1A1ALOX15HTT | |
| SCHEMBL25307003 | 0.74 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| EP-1902022-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007018-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | ERN1 4396/4885L3MBTL1 4125/4885METAP2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.